This record was last updated August 7, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Sepsis is one of the leading causes of hospital mortality, with a rate of approximately 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards. Currently, diagnostic criteria such as the Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack sufficient specificity and accuracy. No established parameters are available for early and timely diagnosis. This study aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes previously validated for non-invasive glucose monitoring. The acquired data will be analyzed using the Anritsu VectorStar VNA to identify innovative and reliable parameters associated with the presence of severe infections.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-06; most recent amendment 2025-08-06.
Status change: Not Yet Recruiting → Recruiting2025-08-06